Neuropharmacology and analgesia
Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography

https://doi.org/10.1016/0014-2999(95)00633-8Get rights and content

Abstract

The central benzodiazepine receptor occupancy by zolpidem in man is unknown. The present study used positron emission tomography (PET) and [11C]flumazenil to assess in five healthy volunteers, central benzodiazepine receptor occupancy in brain regions with high receptor densities 1 h following an acute oral administration of twice the usual hypnotic dose of zolpidem (20 mg). Receptor occupancy was measured in five discrete structures (middle frontal gyrus, middle temporal gyrus, posterior occipital cortex, lateral parietal cortex, and cerebellar cortex) and in a large neocortical area as the fractional change in the [11C]flumazenil bound/free ratio for the interval 15–40 min post-administration of the radiotracer. The free-radioligand concentration was estimated from the pons, a reference structure virtually devoid of central benzodiazepine receptor. With individual pons values, mean occupancy was about 21% but with spurious inter-subject variability. With pons values averaged across the five subjects and separately for control and treated condition, the occupancy was (mean ± S.D.) 27 ± 11% for the whole neocortex, and ranged from 26 to 29% in the five discrete structures (P < 0.01). By showing hypnotic effect at moderate occupancies, this study directly provides evidence for the full-agonist properties of zolpidem in human.

References (41)

  • P. Abadie et al.

    In vivo studies of the central benzodiazepine receptors in the human brain with positron emission topography

  • P. Abadie et al.

    Central benzodiazepine receptors in human brain: estimation of regional Bmax and Kd values with positron emission tomography

    Eur. J. Pharmacol.

    (1992)
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders

    (1987)
  • J. Benavides et al.

    In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15 1788 in the mouse brain

    Preferential affinity of zolpidem for the ω1 (BZ1) subtype

    J. Pharmacol. Exp. Ther.

    (1988)
  • J. Benavides et al.

    Comparative in vivo and in vitro regional selectivity of central ω (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system

    J. Pharmacol. Exp. Ther.

    (1992)
  • A. Cudennec et al.

    The effects of an imidazopyridine hypnotic, zolpidem, on cerebral blood flow and metabolism in primates and rats

  • D. Debruyne et al.

    Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C]Ro 15 1788 (flumazenil) in baboon and human during positron emission tomography studies

    Eur. J. Drug Metab. Pharmacokin.

    (1991)
  • J. Delforge et al.

    Modeling analysis of [11C]flumazenil kinetics in human brain using the multi-injection approach

    J. Cereb. Blood Flow Metab.

    (1993)
  • T. Dennis et al.

    Distribution of central ω1 (benzodiazepine1) and ω2 (benzodiazepine2) receptor subtypes in the monkey and human brain

    An autoradiographic study with [3H]zolpidem and the ω1 seléctive ligand [3H]flunitrazepam

    J. Pharmacol. Exp. Ther.

    (1988)
  • H. Depoortere et al.

    Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioural effects

    J. Pharmacol. Exp. Ther.

    (1986)
  • Cited by (45)

    • Nonhuman Primate Models of Drug and Alcohol Addiction

      2012, Nonhuman Primates in Biomedical Research: Diseases: Second Edition
    • Target site occupancy: Emerging generalizations from clinical and preclinical studies

      2009, Pharmacology and Therapeutics
      Citation Excerpt :

      11C]Flumazenil PET studies with GABAA BZD site ligands demonstrate that ion channel positive allosteric modulators (PAMs, which serve to increase responses to agonists) can require very little target occupancy to elicit a therapeutic effect. Human volunteer studies with clinically-relevant doses of the GABAA PAMs alprazolam, zolpidem and lorazepam, which all demonstrate high levels of intrinsic activity, showed 16%, 26–29% and 5.6% receptor occupancies, respectively (Abadie et al., 1996; Fujita et al., 1999; Lingford-Hughes et al., 2005 and Fig. 6). Therapeutically relevant doses of lorazepam have also been shown to produce negligible occupancy in non-human primate studies using [123I]iomazenil SPECT (Sybirska et al., 1993) and [11C]flumazenil micro-PET (Atack et al., 2007).

    • In Vivo Characterization and Dynamic Receptor Occupancy Imaging of TPA023B, an α2/α3/α5 Subtype Selective γ-Aminobutyric Acid-A Partial Agonist

      2008, Biological Psychiatry
      Citation Excerpt :

      Moreover, up to 20% differences in plasma concentration for this drug are present with comparable receptor occupancy, showing that direct determination of VT on the basis of receptor imaging data might be a more suitable outcome parameter with less intersubject variability. The fact that TPA023B was well-tolerated even at relatively high (50%) levels of occupancy contrasts with classical BZP-site agonists in which therapeutic benefits are observed at low levels of occupancy of, for example, lorazepam (<10%) (34) and sedation is seen in the region of 35% or less for midazolam (30), 24% for diazepam (35), 15%–24% for clonazepam (36), or 21% for zolpidem (37). These data clearly, therefore, highlight the novel pharmacological profile of TPA023B and might be attributed to the partial agonism at the α2, α3, and α5 subtypes and/or the lack of efficacy at the α1 subtype.

    View all citing articles on Scopus
    View full text